Working…
Help guide our efforts to modernize ClinicalTrials.gov.
Send us your comments by March 14, 2020.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Preliminary Study to Investigate the Effect of rTMS and SSRI Antidepressants on Leukocyte Expression of the C-FOS and DUSP1 Genes in Patients Treated for Depression (TMSFOS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02042573
Recruitment Status : Unknown
Verified January 2013 by Centre Hospitalier Universitaire Dijon.
Recruitment status was:  Recruiting
First Posted : January 23, 2014
Last Update Posted : January 23, 2014
Sponsor:
Information provided by (Responsible Party):
Centre Hospitalier Universitaire Dijon

Brief Summary:

Low frequency rTMS (repetitive Transcranial Magnetic Stimulation) for the treatment of patients with depression, is responsible for a decrease in the expression of the C-FOS and DUSP1 genes in peripheral blood leukocytes. The decrease in C-FOS expression could be explained by the inhibiting effect of low-frequency rTMS (in contrast, high-frequency rTMS causes activation of the cerebral cortex) [Rossi, 2009]. This genetic effect could correlate with the antidepressant effect [Hausmann, 2000].

According to this hypothesis, the genetic effect related to medical antidepressant treatments deserves to be studied because we could observe:

  • either a decrease in the expression of the C-FOS and DUSP1 genes related to the antidepressant effect of the medical antidepressant treatment,
  • or an increase in the expression of the C-FOS and DUSP1 genes related to cerebral activation due to the medical antidepressant treatment.

In summary, we wish to determine the validity of this hypothesis by comparing the genetic effect of rTMS with that of medical antidepressants to know if:

  • this genetic effect is specific to rTMS or common rTMS and medical antidepressants
  • this effect correlates with the clinical improvement induced by rTMS and by medical antidepressants
  • this early modification in the C-FOS and DUSP1 genes may be predictor of the therapeutic response to rTMS and antidepressants (early decrease in gene expression)
  • the absence of any decrease or increase in C-FOS and /or DUSP1 expression is a predictor of therapeutic resistance to rTMS and/or medical antidepressants.

Condition or disease Intervention/treatment Phase
Depression Device: rTMS Drug: SSRI (SEROPLEX ou ZOLOFT) Other: Genetic samples Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 60 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Official Title: TMSFOS: Preliminary Study to Investigate the Effect of rTMS and SSRI Antidepressants on Leukocyte Expression of the C-FOS and DUSP1 Genes in Patients Treated for Depression
Study Start Date : November 2013
Estimated Primary Completion Date : January 2015

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Depressive patients treated with rTMS Device: rTMS
Other: Genetic samples
Depressive patients treated with SSRI Drug: SSRI (SEROPLEX ou ZOLOFT)
Other: Genetic samples
Controls Other: Genetic samples



Primary Outcome Measures :
  1. Leukocyte expression of the C-FOS and DUSP1 genes [ Time Frame: At 2, 4 and 8 weeks of treatment with rTMS or an SSRI antidepressant ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

Depressive patients to be treated with rTMS or SSRI:

  • who have provided written informed consent
  • who are covered by the national health insurance scheme
  • who suffer from characterized depression (DSM-IV criteria) that is considered severe (Hamilton-17 item scale ≥ 19)
  • who are aged 18-65 years,
  • male or female
  • who have presented at least one failed treatment with medical antidepressants prescribed at an effective dosage for a duration of at least 6 weeks.

Controls:

  • Patients who have provided written informed consent
  • who are covered by the national health insurance scheme
  • aged between 18 and 65 years
  • and either male or female

Exclusion Criteria:

Depressive patients destined to benefit from treatment with rTMS or SSRI:

  • Type I or II bipolar disorders
  • Depression with characteristics of psychosis
  • Schizophrenia
  • Abuse of alcohol and/or illegal psycho-active substances.
  • Dependence on alcohol and/or an illegal psycho-active substance.
  • Patients unable to provide consent to the protocol because of their mental disorders cannot be included in this study: patients with enforced psychiatric care (SDT, SDRE) or under ward of court.
  • Contra-indication for rTMS; personal history of convulsions, pacemaker, neurosurgical clips, carotid or aortic clips, cardiac valves, audition prostheses, ventricular derivation valve, sutures with metallic thread or staples, foreign bodies in the eye, shrapnel, protheses or cephalic ferromagnetic implants, metal workers.
  • Contra-indication for cerebral MRI
  • Resistance to escitalopram or sertraline (prescription of escitalopram at 20 mg/d or sertraline at 50 mg/d for at least 6 weeks for the last episode)
  • Contra-indication

    • for escitalopram : Hypersensitivity to escitalopram or one of the excipients. non-selective and irreversible monoamine oxidase (IMAO) inhibitors, because of the risk of serotoninergic syndrome with agitation, trembling, hyperthermia. reversible MAO-A inhibitors (e.g.: moclobemide) or a non-selective reversible MAO inhibitor (linezolid), given the risk of a serotoninergic syndrome
    • and to sertraline: Hypersensitivity to one of the components, Hypersensitivity to soja, Hypersensitivity to arachides, Treatment with IMAO
  • Current pregnancy or breast-feeding: an assay for urinary beta-HCG will be done before inclusion in the protocol for women of child-bearing age.
  • Contra-indication for escitalopram:

    • Hypersensitivity to escitalopram or to one of the excipients. No-selective, irreversible monoamine oxidase (IMAO), because of the risk of serotoninergic syndrome with agitation, trembling and hyperthermia.
    • Reversible MAO-A inhibitors (e.g.: moclobemide) or non-selective reversible MAO inhibitors (linezolid), because of the risk of serotoninergic syndrome.
    • Patients presenting an acquired or congenital prolonged QT interval and patients on treatments known to prolong or suspected of prolonging the QT interval (list of treatments on azcert.org).
  • Contra-indication to sertraline:

    • Hypersensitivity to one of the components, Hypersensitivity to soja, Hypersensitivity to arachides, Treatment with IMAO. Patients treated with pimozide.

Controls:

  • Any current psychiatric disease or a history of psychiatric disease (defined by DSM-IV-TR criteria)
  • Current addiction (except for occasional smoking) or a history of addiction (defined by DSM-IV-TR criteria)
  • Any progressive somatic disease (cardiac, hepatic, renal, pulmonary…)
  • Any pharmacological treatment with the exception of combined oral contraceptive pills
  • Current pregnancy or breast-feeding: urinary beta-HCG will be assayed before inclusion in the protocol in women of child-bearing age.
  • Personnel employed in the psychiatry and addictology department of Dijon CHU

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02042573


Contacts
Layout table for location contacts
Contact: Benoît TROJAK 3.80.29.37.69 ext +33 benoit.trojak@chu-dijon.fr

Locations
Layout table for location information
France
CHU de Dijon Recruiting
Dijon, France, 21079
Contact: Benoît TROJAK    3.80.29.37.69 ext +33    benoit.trojak@chu-dijon.fr   
Sponsors and Collaborators
Centre Hospitalier Universitaire Dijon

Layout table for additonal information
Responsible Party: Centre Hospitalier Universitaire Dijon
ClinicalTrials.gov Identifier: NCT02042573    
Other Study ID Numbers: TROJAK APJ 2012
First Posted: January 23, 2014    Key Record Dates
Last Update Posted: January 23, 2014
Last Verified: January 2013
Additional relevant MeSH terms:
Layout table for MeSH terms
Depression
Depressive Disorder
Behavioral Symptoms
Mood Disorders
Mental Disorders
Antidepressive Agents
Psychotropic Drugs